STAAR Surgical Company Form 10-Q Summary
Business context and reporting period
The filing covers the quarter ended March 30, 2012, although the request metadata identifies “2011 Q1.” STAAR designs, manufactures, and sells implantable ophthalmic lenses and related surgical products. It operates as one ophthalmic surgical product segment, with sales in approximately 60 countries. International sales represented approximately 80% of quarterly revenue.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net sales | $15.5 million | $14.8 million | +4.4% |
| Gross profit | $10.9 million | $9.6 million | +13.2% |
| Gross margin | 70.3% | 64.8% | +5.5 percentage points |
| Operating income | $0.3 million | $0.2 million | +33.7% |
| Net income | $0.2 million | $0.3 million | -22.6% |
| Diluted earnings per share | $0.01 | $0.01 | Unchanged |
| Operating cash flow | $(0.4) million | $0.6 million | Declined |
ICL sales increased 24.8% to $8.6 million and represented 55.5% of sales. IOL sales declined 10.7% to $6.4 million, while other surgical product sales declined 34.4% to $0.5 million. The improved gross margin reflected the higher-margin ICL product mix and IOL cost improvements.
General and administrative expense rose 13.6% to $3.9 million, marketing and selling expense rose 4.6% to $4.7 million, and research and development expense rose 8.0% to $1.5 million. Other general and administrative expenses increased to $0.6 million, primarily from manufacturing-consolidation costs. Stock-based compensation increased to $0.7 million from $0.4 million.
Cash and cash equivalents were $16.4 million at March 30, 2012, compared with $16.6 million at December 30, 2011. Cash declined by $0.1 million during the quarter. Operating cash use reflected working-capital investment, including increases in inventory and prepaids and decreases in accounts payable and other current liabilities. Investing cash use was $0.2 million, including $0.3 million of capital expenditures. Financing activities provided $0.6 million, principally from stock-option exercises.
The company had $2.4 million outstanding under its Japanese line of credit, with approximately $1.2 million available, and no borrowings under its approximately $1.1 million Swiss facility. Capital lease obligations totaled $1.6 million, including $0.9 million current. Management stated that the company was in compliance with its credit-facility covenants and believed existing cash and operating cash flow would fund foreseeable requirements, including the manufacturing-consolidation program.
Material changes versus the prior comparable period
- Revenue grew modestly, driven by strong ICL growth, while IOL and lower-margin other-product sales declined.
- Gross margin improved materially from 64.8% to 70.3%.
- Operating income improved, but net income declined because other income was lower, particularly foreign-exchange gains.
- Operating cash flow changed from $0.6 million provided to $0.4 million used.
- Foreign-currency translation and pension adjustments produced other comprehensive loss of $0.5 million, resulting in comprehensive loss of $0.3 million.
- Accounts payable decreased by $1.2 million and inventories increased by $0.2 million from year-end.
Guidance, outlook, commentary, risks, and unusual items
Management’s 2012 operating targets were 15% total-revenue growth, at least 32% ICL sales growth, a 71% full-year gross margin, profitability in all four quarters, and completion of manufacturing consolidation without material customer-supply disruption. In Q1, revenue growth was 4%, core-product growth was 7%, ICL growth was 25%, and gross margin was 70.3%. Management reported fifth-consecutive-quarter profitability but cautioned that sustained profitability remained vulnerable.
The company plans to consolidate manufacturing into Monrovia by the end of 2013. The initiative and related tax strategy are expected to cost approximately $6.0 million over three years, including approximately $2.4 million of capital expenditures. Approximately $1.6 million had been incurred through the quarter, including approximately $0.6 million during Q1. The company had accrued $0.3 million of termination benefits and expected total severance of approximately $1.5 million.
Key risks include elective-procedure demand and economic conditions, foreign-exchange movements, regulatory approvals, international operating and political risks, manufacturing-transfer delays or supply interruptions, product liability, reimbursement changes affecting IOLs, and competitive pressure. The FDA’s review of the U.S. Toric ICL application remained unresolved; the company stated that it could not predict whether or when approval would be granted. The company also stated that it had no material off-balance-sheet arrangements and that its disclosure controls were effective.
Important facts for investors to verify
- Confirm the reporting-period discrepancy: the filing is for Q1 2012, ended March 30, 2012, not Q1 2011.
- Assess whether ICL growth can offset continued IOL and other-product declines and support the 15% full-year revenue target.
- Monitor progress, total spending, supply continuity, and realized savings from the manufacturing consolidation.
- Reconcile positive net income with negative operating cash flow and evaluate working-capital requirements.
- Track the FDA status of the U.S. Toric ICL application and other regulatory approvals.
- Evaluate exposure to foreign currency, international markets, elective-procedure demand, and reimbursement changes.
- Review the impact of rising stock-based compensation and equity dilution, including 38.4 million diluted weighted-average shares.